2023 World Conference on Lung Cancer (Posters)-P2.20. The Impact of Preoperative Immunotherapy On Peri-Operative Outcomes After Thymectomy for Thymic Epithelial Tumors

P2.20. The Impact of Preoperative Immunotherapy On Peri-Operative Outcomes After Thymectomy for Thymic Epithelial Tumors - PDF(Slides)

Back to course

Pdf Summary

This article discusses the impact of preoperative immunotherapy on peri-operative outcomes after thymectomy for thymic epithelial tumors (TET). The study aimed to evaluate the use of preoperative immunotherapy prior to thymectomy and its effect on perioperative and oncologic outcomes. The researchers used the National Cancer Database (NCDB) from 2004 to 2020 as their data source. The primary endpoint was major perioperative morbidity, defined as perioperative mortality, hospital length of stay (LOS), and readmission.<br /><br />The results demonstrated that the use of preoperative immunotherapy for TET did not delay surgery, indicating favorable tolerability. It was also not associated with worse perioperative morbidity. However, the study acknowledged that it reflected early experience with preoperative immunotherapy and called for ongoing investigations to expand treatment options in TET.<br /><br />The article highlighted the need for further research to better understand the mechanisms of response and resistance to immunotherapy and to identify which patients are most likely to benefit. It suggested that additional studies should focus on these areas to improve outcomes in the future. The article also presented data comparing different treatment modalities, including chemoradiation, chemotherapy, and immunotherapy, in terms of diagnostic-to-surgery time, mortality rates, hospital length of stay, readmission rates, complications, and positive margins.<br /><br />On multivariable logistic regression analysis, the study found that the use of immunotherapy versus standard chemotherapy was not an independent predictor of complicated perioperative course, pathological complete response, or R0 resection.<br /><br />Overall, this study contributes to the growing body of knowledge on the use of preoperative immunotherapy in TET. While the results suggest favorable tolerability and no significant negative impact on perioperative outcomes, further research is needed to fully understand its effectiveness and identify optimal patient selection criteria.

Asset Subtitle

Lye-Yeng Wong

Meta Tag

Speaker Lye-Yeng Wong

Topic Thymic Malignancy

Keywords

preoperative immunotherapy

thymectomy

thymic epithelial tumors

perioperative outcomes

oncologic outcomes

National Cancer Database

major perioperative morbidity

tolerability

mechanisms of response

resistance to immunotherapy